Table 1 Baseline characteristics, n = 200 patients
From: COVID-19 related deaths in an urban academic medical center in Brooklyn – a descriptive case series
| Age in years, median (IQR) | 73 (62–82) |
| Breakdown by age group (n, %) | |
| ≤ 39 | 3 (1·5) |
| 40–59 | 26 (13) |
| 60–79 | 107 (53·5) |
| 80–89 | 49 (24·5) |
| > 89 | 15 (7·5) |
| Male (n, %) | 117 (58·5) |
| Race (n, %) | |
| Black | 178 (89) |
| Latino | 7 (3·5) |
| White | 4 (2) |
| Undisclosed | 11 (5·5) |
| Origin (n, %) | |
| Home | 179 (89·5) |
| Nursing home | 21 (10·5) |
| Admitted to hospital for reasons other than COVID-19 (n, %) | 11 (5·5) |
| Weight | |
| TBW, median (IQR), kg | 77.6 (68·55–90·7) |
| BMI, median (IQR), kg/m2 | 29 (25·1–32·9) |
| Breakdown by BMI (n, %) | |
| Underweight (< 18.5) | 4 (2) |
| Normal weight (18.5–24.9) | 45 (22·5) |
| Overweight (25–29.9) | 68 (34) |
| Obese (≥ 30) | 83 (41·5) |
| Past Medical History (n, %) | |
| Hypertension | 169 (84·5) |
| Diabetes mellitus | 115 (57·5) |
| Hypertension and diabetes mellitus | 101 (50·5) |
| Obesity | 83 (41·5) |
| Coronary artery disease | 49 (24·5) |
| Chronic kidney disease or end-stage renal disease | 40 (20) |
| On hemodialysis prior to admission | 14 (7) |
| Cerebral vascular disease | 28 (14) |
| Asthma | 16 (8) |
| COPD | 17 (8·5) |
| History of malignancy | 12 (6) |
| HIV-positive | 7 (3·5) |
| Renal transplant | 4 (2) |
| Known current or former smoker | 19 (9·5) |
| History of ACE inhibitor/ARB use | 59 (29·5) |
| No known past medical history, not obese | 13 (6·5) |
| Number of comorbiditiesa (n, %) | |
| No comorbidities | 10 (5) |
| 1 comorbidity | 28 (14) |
| 2 comorbidities | 52 (26) |
| 3 comorbidities | 54 (27) |
| 4 or more comorbidities | 56 (28) |
| More than 1 comorbidity | 162 (81) |
| Three or more comorbidities | 110 (55) |